Structure-based peptide mimicry of tumor-associated antigens

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 32, Issue 1, 2013, Pages 1-5

  Ohtaki, Akashi ^a   Kieber Emmons, Thomas ^b   Murali, Ramachandran ^a,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; DISIALOGANGLIOSIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GANGLIOSIDE; PEPTIDE VACCINE; PERTUZUMAB; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; BLOOD GROUP LEWIS SYSTEM; BREAST CANCER; DRUG SYNTHESIS; HUMAN; MOLECULAR MIMICRY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL SURFACE DISPLAY TECHNIQUES; EPITOPES, B-LYMPHOCYTE; FEMALE; GANGLIOSIDES; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MOLECULAR MIMICRY; RECEPTOR, ERBB-2;

EID: 84876774466     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2012.0076     Document Type: Article

References (43)

1. Harrison C: Vaccines: Structure-based design. Nat Rev Drug Discov 2011;10(9):658.
2. Laune D, Molina F, Ferrieres G, Villard S, Bes C, Rieunier F, Chardes T, and Granier C: Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. J Immunol Methods 2002;267(1):53-70.
3. Murali R, Sharkey DJ, Daiss JL, and Murthy HM: Crystal structure of Taq DNA polymerase in complex with an inhibitory Fab: The Fab is directed against an intermediate in the helix-coil dynamics of the enzyme. Proc Natl Acad Sci USA 1998;95(21):12562-12567.
4. Saha S, and Raghava GP: Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 2006;65(1):40-48.
5. Irving MB, Craig L, Menendez A, Gangadhar BP, Montero M, van Houten NE, and Scott JK: Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes. Mol Immunol 2010;47(5):1137-1148.
6. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PW, Burton DR, Scott JK, and Wilson IA: Structure of a high-affinity ''mimotope'' peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 2007;369(3):696-709.
7. Enshell-Seijffers D, and Gershoni JM: Phage display selection and analysis of Ab-binding epitopes. Curr Protoc Immunol 2002;Ch 9, Unit 8.
8. Freund NT, Enshell-Seijffers D, and Gershoni JM: Phage display selection, analysis, and prediction of B cell epitopes. Curr Protoc Immunol 2009; Ch 9, Unit 8.
9. Gershoni JM, Roitburd-Berman A., Siman-Tov DD, Tarnovitski Freund N, and Weiss Y: Epitope mapping: The first step in developing epitope-based vaccines. BioDrugs 2007;21(3):145-156.
10. Srinivasan A, Ayyavoo V, Mahalingam S, Kannan A, Boyd A, Datta D, Kalyanaraman VS, Cristillo A, Collman RG, Morellet N, Sawaya BE, and Murali R: A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes. Virol J 2008;5:99.
11. Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF, and Kieber- Emmons T: Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine 2007;25(16):3022-3031.
12. Murali R, and Kieber-Emmons T: Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody. J Mol Recognit 1997;10(6):269-276.
13. Irving MB, Pan O, and Scott JK: Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol 2001;5(3):314-324.
14. Luo P, Canziani G, Cunto-Amesty G, and Kieber-Emmons T: A molecular basis for functional peptide mimicry of a carbohydrate antigen. J Biol Chem 2000;275(21):16146-16154.
15. Cunto-Amesty G, Dam TK, Luo P, Monzavi-Karbassi B, Brewer CF, Van Cott TC, and Kieber-Emmons T: Directing the immune response to carbohydrate antigens. J Biol Chem 2001;276(32):30490-30498.
16. Baselga J, Norton L, Albanell J, Kim YM, and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58(13):2825-2831.
17. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, and Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5(4):317-328.
18. Miyako H, Kametani Y, Katano I, Ito R, Tsuda B, Furukawa A, SaitoY, Ishikawa D, Ogino K, Sasaki S, Imai K, Habu S, Makuuchi H, and Tokuda Y: Antitumor effect of new HER2 peptide vaccination based on B cell epitope. Anticancer Res 2011;31(10):3361-3368.
19. Zhou H, Zha Z, Liu Y, Zhang H, Zhu J, Hu S, Shen G, Cheng L, Niu L, Greene MI, Teng M, and Liu J: Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21. J Biol Chem 2011;286(36):31676-31683.
20. Yarden Y: Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci USA 1990;87(7):2569-2573.
21. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, and Jensen- Jarolim E: Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/ neu. J Immunol 2004;173(1):394-401.
22. Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa 4 OHTAKI ET AL. D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii- Saab TS, and Carson WE III: Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous Tcell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009;27(31):5270- 5277.
23. Ragupathi G: Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 1996; 43(3):152-157.
24. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, and Rittenhouse-Olson K: Cancer vaccines and carbohydrate epitopes. Vaccine 2011;29(48):8802-8826.
25. Qiu J, Luo P, Wasmund K, Steplewski Z, and Kieber-Emmons T: Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma 1999;18(1): 103-112.
26. Hoess R, Brinkmann U, Handel T, and Pastan I: Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993;128(1):43-49.
27. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, and Gallop MA: Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci USA 1992;89(12):5393-5397.
28. Jain D, Kaur K, Sundaravadivel B, and Salunke DM: Structural and functional consequences of peptide-carbohydrate mimicry. Crystal structure of a carbohydrate-mimicking peptide bound to concanavalin A. J Biol Chem 2000;275(21): 16098-16102.
29. Luo P, Agadjanyan M, Qiu J, Westerink MA, Steplewski Z, and Kieber-Emmons T: Antigenic and immunological mimicry of peptide mimotopes of Lewis carbohydrate antigens. Mol Immunol 1998;35(13):865-879.
30. Pichla SL, Murali R, and Burnett RM: The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J Struct Biol 1997;119(1):6-16.
31. Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, and Herlyn D: Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 2008;57(7):1079-1089.
32. Fields BA, Goldbaum FA, Ysern X, Poljak RJ, and Mariuzza RA: Molecular basis of antigen mimicry by an anti-idiotope. Nature 1995;374(6524):739-742.
33. Braden BC, Fields BA, Ysern X, Dall'Acqua W, Goldbaum FA, Poljak RJ, and Mariuzza RA: Crystal structure of an Fv- Fv idiotope-anti-idiotope complex at 1.9A resolution. J Mol Biol 1996;264(1):137-151.
34. Kieber-Emmons T, Murali R, and Greene MI: Therapeutic peptides and peptidomimetics. Curr Opin Biotechnol 1997; 8(4):435-441.
35. MacCallum RM, Martin AC, and Thornton JM: Antibodyantigen interactions: Contact analysis and binding site topography. J Mol Biol 1996;262(5):732-745.
36. Kwong PD, and Shapiro L: Vaccine design reaches the atomic level. Sci Transl Med 2011;3(91):91ps29.
37. Sattentau QJ, and McMichael AJ: New templates for HIV-1 antibody-based vaccine design. F1000 Biol Rep 2010;2:60.
38. Van Regenmortel MH: Limitations to the structure-based design of HIV-1 vaccine immunogens. J Mol Recognit 2011; 24(5):741-753.
39. Kunik V, Peters B, and Ofran Y: Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol 2012;8(2):e1002388.
40. Menendez A, Calarese DA, Stanfield RL, Chow KC, Scanlan CN, Kunert R, Katinger H, Burton DR, Wilson IA, and Scott JK: A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J 2008;22(5):1380-1392.
41. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, and Serino L: Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA 2010;107(20):9072- 9077.
42. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, Palumbo E, Veggi D, Ciucchi L, Cartocci E, Bottomley MJ Malito E, Lo Surdo P, Comanducci M, Giuliani M, Cantini F, Dragonetti S, Colaprico A, Doro F, Giannetti P, Pallaoro M, Brogioni B, Tontini M, Hilleringmann M, Nardi-Dei V, Banci L, Pizza M, and Rappuoli R: Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 2011;3(91):91ra62.
43. Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, and Murali R: Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem 2002;277(31):28330- 28339.